{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT02675829",
            "orgStudyIdInfo": {
                "id": "15-335"
            },
            "organization": {
                "fullName": "Memorial Sloan Kettering Cancer Center",
                "class": "OTHER"
            },
            "briefTitle": "Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers",
            "officialTitle": "A Phase 2 Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "trial-of-ado-trastuzumab-emtansine-for-patients-with-amplified-or-mutant-cancers"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2016-02",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-02",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-02",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2016-02-03",
            "studyFirstSubmitQcDate": "2016-02-03",
            "studyFirstPostDateStruct": {
                "date": "2016-02-05",
                "type": "ESTIMATED"
            },
            "lastUpdateSubmitDate": "2024-05-07",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-08",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Memorial Sloan Kettering Cancer Center",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Genentech, Inc.",
                    "class": "INDUSTRY"
                }
            ]
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to find out what effects, a drug called ado-trastuzumab emtansine has on the patient and their cancer which is thought to be controlled by the abnormal HER2 gene."
        },
        "conditionsModule": {
            "conditions": [
                "Solid Tumor Cancers",
                "Lung Cancer",
                "Bladder Cancer",
                "Urinary Tract Cancers"
            ],
            "keywords": [
                "HER2 mutant",
                "HER2 amplified",
                "Ado-Trastuzumab Emtansine",
                "15-335"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 140,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Cohort 1: Lung cancers, HER2 mutant",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: ado-trastuzumab emtansine"
                    ]
                },
                {
                    "label": "Cohort 2: Lung cancers, HER2 amplified",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: ado-trastuzumab emtansine"
                    ]
                },
                {
                    "label": "Cohort 3: Colorectal cancers",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: ado-trastuzumab emtansine"
                    ]
                },
                {
                    "label": "Cohort 4: Endometrial cancers",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: ado-trastuzumab emtansine"
                    ]
                },
                {
                    "label": "Cohort 5: Salivary gland cancers",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: ado-trastuzumab emtansine"
                    ]
                },
                {
                    "label": "Cohort 6: Other solid cancers",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: ado-trastuzumab emtansine"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "ado-trastuzumab emtansine",
                    "description": "Ado-trastuzumab emtansine is administered intravenously at 3.6 mg/kg every 21 days (unless dose reduction and/or dose delays are required) until disease progression or unacceptable toxicity.",
                    "armGroupLabels": [
                        "Cohort 1: Lung cancers, HER2 mutant",
                        "Cohort 2: Lung cancers, HER2 amplified",
                        "Cohort 3: Colorectal cancers",
                        "Cohort 4: Endometrial cancers",
                        "Cohort 5: Salivary gland cancers",
                        "Cohort 6: Other solid cancers"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "best overall response (ORR)",
                    "description": "As soon as evaluations for each tumor assessment are completed, the Investigator should assess the patient's overall response (target plus non- target lesions) based on criteria and overall response algorithms as defined in RECIST version 1.1. Scans must be assessable for all evaluations.",
                    "timeFrame": "2 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Adults who are \u226518 years old.\n* Pathologically confirmed advanced solid tumor cancers\n* For Cohort 1, documented activating HER2 mutation in lung cancer by CLIA laboratory, specifically exon 20 insYVMA (Y772_A775dup), insGSP (G778_P780dup), insTGT (G776delinsVC), single base pair substitutions L755A, L755S, V777L, V659E, S310F, or another HER2 mutation approved by the Principal Investigator\n* For Cohorts 2, 3, 4, 5, 6 documented HER2 amplification identified through next generation sequencing by MSK-IMPACT or at another Clinical Laboratory Improvement Amendments (CLIA) laboratory, or documented HER2 amplification by in-situ hybridization (ISH) with HER2/CEP17 ratio \u22652.0 at a CLIA laboratory. Patients with HER2 amplification identified by another method or criteria must be approved by the Principal Investigator and may enroll in the \"Other\" Cohort 4.\n* Measurable or evaluable indicator lesion(s) as defined by RECIST v1.1. Patients without RECIST measurable disease will be eligible for enrollment to \"Other\" cohort provided their disease can be evaluated using another accepted response criteria (e.g. Gynecologic Cancer InterGroup (GCIG) CA125 Response Criteria, modified PET Response Criteria in Solid Tumors (PERCIST)). Patients with salivary gland cancers (Cohort 5) may be eligible on the basis of evaluable disease on modified PET.\n* Karnofsky Performance Status 70% or above.\n* Left ventricular ejection fraction (LVEF) \u226550% measured by echocardiogram (ECHO) or multiple gated acquisition scan (MUGA).\n* Negative \u03b2-human chorionic gonadotropin (hCG) pregnancy test within 2 weeks before enrollment for premenopausal women of reproductive capacity and for women less than 12 months after menopause. Pregnancy screening will be conducted for women up to the age of 50 years per institutional standard.\n* Women of childbearing potential must agree to use of a highly effective method of contraception. Effective contraception is required during treatment and for 7 months following the last dose for female participants of reproductive potential and during treatment and for 4 months following the last dose for male participants with female sexual partners of reproductive potential. Male participants should also refrain from donating sperm during treatment and for 4 months following the last dose.\n* Absolute neutrophil count \u2265 1,000/\u00b5L within 30 days prior to C1D1\n* Platelet count \u2265 100,000/\u00b5L within 30 days prior to C1D1\n* Total bilirubin \u2264 1.5 x institutional upper limit of normal (ULN), in case of Gilbert's syndrome, \u2264 2x ULN within 30 days prior to C1D1\n* Aspartate aminotransferase and/or alanine aminotransferase \u2264 3 x ULN (\u2264 5 x ULN if liver metastases are present) within 30 days prior to C1D1\n* Provide written, informed consent to participate in the study and follow the study procedures\n\nExclusion Criteria:\n\n* Prior therapy resulting in cumulative epirubicin dose \u2265 900mg/m2 or cumulative doxorubicin dose \u2265 500mg/m2 or equivalent dose of another anthracycline.\n* Prior therapy with ado-trastuzumab emtansine (patients who had prior trastuzumab or other HER2 targeted agents are eligible).\n* Symptomatic congestive heart failure (New York Heart Association Classification II-IV).\n* Myocardial infarction or unstable angina within 6 months of enrollment.\n* Unstable ventricular arrhythmia requiring treatment.\n* Grade 3 or worse peripheral neuropathy as defined by CTCAE v4.1.\n* Women who are pregnant or breast-feeding.\n* Known hypersensitivity to any component of ado-trastuzumab emtansine.\n* History of interstitial lung disease or pneumonitis.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Bob Li, MD",
                    "role": "CONTACT",
                    "phone": "646-608-3791"
                },
                {
                    "name": "Gopakumar Iyer, MD",
                    "role": "CONTACT",
                    "phone": "646-422-4362"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Bob Li, MD",
                    "affiliation": "Memorial Sloan Kettering Cancer Center",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)",
                    "status": "RECRUITING",
                    "city": "Basking Ridge",
                    "state": "New Jersey",
                    "zip": "07920",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Bob Li, MD",
                            "role": "CONTACT",
                            "phone": "646-608-3791"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.70621,
                        "lon": -74.54932
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Monmouth (Limited Protocol Activities)",
                    "status": "RECRUITING",
                    "city": "Middletown",
                    "state": "New Jersey",
                    "zip": "07748",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Bob Li, MD",
                            "role": "CONTACT",
                            "phone": "646-608-3791"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.39652,
                        "lon": -74.09211
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Bergen (Limited Protocol Activities)",
                    "status": "RECRUITING",
                    "city": "Montvale",
                    "state": "New Jersey",
                    "zip": "07645",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Bob Li, MD",
                            "role": "CONTACT",
                            "phone": "646-608-3791"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.04676,
                        "lon": -74.02292
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Cancer Center @ Suffolk - Commack (Limited Protocol Activities)",
                    "status": "RECRUITING",
                    "city": "Commack",
                    "state": "New York",
                    "zip": "11725",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Bob Li, MD",
                            "role": "CONTACT",
                            "phone": "646-608-3791"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.84288,
                        "lon": -73.29289
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Westchester (Limited Protocol Activities)",
                    "status": "RECRUITING",
                    "city": "Harrison",
                    "state": "New York",
                    "zip": "10604",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Bob Li, MD",
                            "role": "CONTACT",
                            "phone": "646-608-3791"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.96899,
                        "lon": -73.71263
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Cancer Center",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10065",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Bob Li, MD",
                            "role": "CONTACT",
                            "phone": "646-608-3791"
                        },
                        {
                            "name": "Gopakumar Iyer, MD",
                            "role": "CONTACT",
                            "phone": "646-422-4362"
                        },
                        {
                            "name": "Bob Li, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Nassau (Limited Protocol Activities)",
                    "status": "RECRUITING",
                    "city": "Uniondale",
                    "state": "New York",
                    "zip": "11553",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Bob Li, MD",
                            "role": "CONTACT",
                            "phone": "646-608-3791"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.70038,
                        "lon": -73.59291
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "32923849",
                    "type": "DERIVED",
                    "citation": "Mondaca S, Razavi P, Xu C, Offin M, Myers M, Scaltriti M, Hechtman JF, Bradley M, O'Reilly EM, Berger MF, Solit DB, Li BT, Abou-Alfa GK. Genomic Characterization of ERBB2-Driven Biliary Cancer and a Case of Response to Ado-Trastuzumab Emtansine. JCO Precis Oncol. 2019 Oct 17;3:PO.19.00223. doi: 10.1200/PO.19.00223. eCollection 2019."
                },
                {
                    "pmid": "29989854",
                    "type": "DERIVED",
                    "citation": "Li BT, Shen R, Buonocore D, Olah ZT, Ni A, Ginsberg MS, Ulaner GA, Offin M, Feldman D, Hembrough T, Cecchi F, Schwartz S, Pavlakis N, Clarke S, Won HH, Brzostowski EB, Riely GJ, Solit DB, Hyman DM, Drilon A, Rudin CM, Berger MF, Baselga J, Scaltriti M, Arcila ME, Kris MG. Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial. J Clin Oncol. 2018 Aug 20;36(24):2532-2537. doi: 10.1200/JCO.2018.77.9777. Epub 2018 Jul 10. Erratum In: J Clin Oncol. 2019 Feb 1;37(4):362. doi: 10.1200/JCO.18.02207."
                }
            ],
            "seeAlsoLinks": [
                {
                    "label": "Memorial Sloan Kettering Cancer Center",
                    "url": "https://www.mskcc.org/"
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000014571",
                    "term": "Urologic Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000014565",
                    "term": "Urogenital Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000052776",
                    "term": "Female Urogenital Diseases"
                },
                {
                    "id": "D000005261",
                    "term": "Female Urogenital Diseases and Pregnancy Complications"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000014570",
                    "term": "Urologic Diseases"
                },
                {
                    "id": "D000052801",
                    "term": "Male Urogenital Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5030",
                    "name": "Urinary Bladder Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M11172",
                    "name": "Lung Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M17320",
                    "name": "Urologic Neoplasms",
                    "asFound": "Urinary Tract Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M17315",
                    "name": "Urogenital Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27093",
                    "name": "Female Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14127",
                    "name": "Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M8399",
                    "name": "Female Urogenital Diseases and Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M17319",
                    "name": "Urologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27095",
                    "name": "Male Urogenital Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000068878",
                    "term": "Trastuzumab"
                },
                {
                    "id": "D000080044",
                    "term": "Ado-Trastuzumab Emtansine"
                },
                {
                    "id": "D000008453",
                    "term": "Maytansine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000000972",
                    "term": "Antineoplastic Agents, Phytogenic"
                },
                {
                    "id": "D000050257",
                    "term": "Tubulin Modulators"
                },
                {
                    "id": "D000050256",
                    "term": "Antimitotic Agents"
                },
                {
                    "id": "D000050258",
                    "term": "Mitosis Modulators"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000922",
                    "term": "Immunotoxins"
                },
                {
                    "id": "D000018796",
                    "term": "Immunoconjugates"
                },
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M325",
                    "name": "Trastuzumab",
                    "asFound": "Follow-up",
                    "relevance": "HIGH"
                },
                {
                    "id": "M3595",
                    "name": "Adenosine",
                    "relevance": "LOW"
                },
                {
                    "id": "M2102",
                    "name": "Ado-Trastuzumab Emtansine",
                    "asFound": "WBC",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11436",
                    "name": "Maytansine",
                    "asFound": "Opioid Use",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M26197",
                    "name": "Tubulin Modulators",
                    "relevance": "LOW"
                },
                {
                    "id": "M26196",
                    "name": "Antimitotic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4241",
                    "name": "Immunotoxins",
                    "relevance": "LOW"
                },
                {
                    "id": "M20855",
                    "name": "Immunoconjugates",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "AnArAg",
                    "name": "Anti-Arrhythmia Agents"
                },
                {
                    "abbrev": "VaDiAg",
                    "name": "Vasodilator Agents"
                },
                {
                    "abbrev": "Analg",
                    "name": "Analgesics"
                }
            ]
        }
    },
    "hasResults": false
}